Page 87 - 《中国药房》2025年16期

vanced breast cancer[J]. N Engl J Med，2022，387（1）： patient-reported outcomes（PROs）from the TROPION-
9-20. Breast01 study[J]. J Clin Oncol，2024，42（Suppl. 16）：
[ 7 ] SELIGSON J M，PATRON A M，BERGER M J，et al. 1006.
Sacituzumab govitecan-hziy：an antibody-drug conjugate [19] WU B，MA F. Cost-effectiveness of adding atezolizumab
for the treatment of refractory，metastatic，triple-negative to first-line chemotherapy in patients with advanced triple-
breast cancer[J]. Ann Pharmacother，2021，55（7）： negative breast cancer[J]. Ther Adv Med Oncol，2020，12：
921-931. 1758835920916000.
[ 8 ] BARDIA A，HURVITZ S A，TOLANEY S M，et al. Saci‐ [20] WANG L，LIU L L，ZHANG Z，et al. Cost-effectiveness
tuzumab govitecan in metastatic triple-negative breast can‐ of sacituzumab govitecan versus single-agent chemo‐
cer[J]. N Engl J Med，2021，384（16）：1529-1541. therapy for patients with metastatic triple-negative breast
[ 9 ] BARDIA A，RUGO H S，TOLANEY S M，et al. Final re‐ cancer in China[J]. Clin Breast Cancer，2024，24（7）：
sults from the randomized phase Ⅲ ASCENT clinical trial e545-e553.e6.
in metastatic triple-negative breast cancer and association [21] ZHU Y W，LIU K，WANG M，et al. Trastuzumab deruxte‐
of outcomes by human epidermal growth factor receptor 2 can versus trastuzumab emtansine for patients with human
and trophoblast cell surface antigen 2 expression[J]. J Clin epidermal growth factor receptor 2-positive metastatic
Oncol，2024，42（15）：1738-1744. breast cancer：a cost-effectiveness analysis[J]. Breast，
[10] YIN Y M，FAN Y，OUYANG Q C，et al. Sacituzumab tiru‐ 2022，66：191-198.
motecan in previously treated metastatic triple-negative [22] LI J B，LIN Z C，WONG M C S，et al. A cost-
breast cancer：a randomized phase 3 trial[J]. Nat Med， effectiveness analysis of capecitabine maintenance
2025，31（6）：1969-1975. therapy versus routine follow-up for early-stage triple-
[11] EISENHAUER E A，THERASSE P，BOGAERTS J，et al. negative breast cancer patients after standard treatment
New response evaluation criteria in solid tumours：revised from a perspective of Chinese society[J]. BMC Med，
RECIST guideline：version 1.1[J]. Eur J Cancer，2009，45 2022，20（1）：320.
（2）：228-247. [23] ZHAN M，HUANG Z J，XU T，et al. Cost-effectiveness
[12] HSU J Y，CHANG C J，CHENG J S. Survival，treatment analysis of trastuzumab deruxtecan in patients with HER2-
regimens and medical costs of women newly diagnosed low advanced breast cancer based on DESTINY-Breast04
with metastatic triple-negative breast cancer[J]. Sci Rep， [J]. Front Public Health，2023，11：1049947.
2022，12（1）：729. [24] ZOU H M，LAI Y F，CHEN X W，et al. Cost-effectiveness
[13] 刘国恩. 中国药物经济学评价指南2020[M]. 北京：中国 of camrelizumab plus rivoceranib versus sorafenib as first-
市场出版社，2020：27-46. line treatment of unresectable hepatocellular carcinoma[J].
[14] 周颖玉，吴群红. 经济学理论视角下的健康贴现率研究 Therap Adv Gastroenterol，2025，18：17562848241310314.
[J]. 中国卫生经济，2023，42（1）：1-3. [25] SHI G H，PARK S H，REN H Y，et al. Cost analysis for
[15] 中国抗癌协会乳腺癌专业委员会，中国抗癌协会国际医 different sequential treatment regimens for metastatic re‐
疗交流分会，中国医师协会肿瘤医师分会乳腺癌学组 . nal cell carcinoma in China[J]. J Med Econ，2018，21
中国晚期三阴性乳腺癌临床诊疗指南：2024版[J]. 中华 （12）：1150-1158.
肿瘤杂志，2024，46（6）：471-480. [26] GAN Y N，SHI F H，ZHU H，et al. Cost-effectiveness of
[16] CAI H F，HUANG L S，ZHENG Z W. Toripalimab plus durvalumab plus tremelimumab in combination with che‐
chemotherapy in the treatment of metastatic triple- motherapy for the treatment of metastatic non-small-cell
negative breast cancer：a cost-effectiveness analysis[J]. lung cancer from the US healthcare sector’s and societal
Front Public Health，2024，12：1421826. perspectives[J]. Front Pharmacol，2024，15：1256992.
[17] 石丰豪，商叶，芮明军，等. R语言survHE程序包在卫生 [27] YUE X M，LI Y X，WU J H，et al. Current development
经济学评价中的应用[J]. 中国卫生经济，2020，39（9）： and practice of pharmacoeconomic evaluation guidelines
9-14. for universal health coverage in China[J]. Value Health
[18] PERNAS S，IM S A，HATTORI M，et al. Datopotamab de‐ Reg Issues，2021，24：1-5.
ruxtecan（Dato-DXd）vs chemotherapy（CT）in previously （收稿日期：2025-01-19 修回日期：2025-07-17）
treated inoperable or metastatic hormone receptor-positive， （编辑：孙 冰）
HER2-negative（HR+/HER2－）breast cancer（BC）：

中国药房 2025年第36卷第16期 China Pharmacy 2025 Vol. 36 No. 16 · 2029 ·